Medulloepithelioma: Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Medulloepithelioma is a rare embryonal neoplasm arising from primitive medullary epithelium — the embryonic precursor of the neural tube and intraocular ciliary epithelium. It occurs in two distinct anatomical settings: intraocular medulloepithelioma, arising from the non-pigmented epithelium of the ciliary body, and intracranial medulloepithelioma, an embryonal CNS tumor classified separately in the 2021 WHO Classification as 'embryonal tumor with multilayered rosettes (ETMR), NOS' when DICER1-mutated. Intraocular medulloepithelioma is the more common form, representing the second most common intraocular tumor in children after retinoblastoma, with a median age of diagnosis around 5 years (range: birth to 10 years). CNS medulloepithelioma is exceedingly rare, with fewer than 100 reported cases, arising predominantly in the posterior fossa, periventricular regions, or cauda equina in children. Both forms may be benign (teratoid: containing heteroplastic elements such as cartilage or brain tissue) or malignant (poorly differentiated, with necrosis and high mitotic index). Prognosis depends on histological grade, completeness of resection, and extent of spread.

The molecular pathogenesis of medulloepithelioma involves dysregulation of primitive neuroepithelial developmental pathways. DICER1 syndrome — caused by germline loss-of-function mutations in the DICER1 gene (a microRNA processing endoribonuclease) — is associated with intraocular medulloepithelioma, as well as pleuropulmonary blastoma, ovarian sex cord-stromal tumors, cystic nephroma, and thyroid carcinoma. Somatic DICER1 mutations are found in the tumor tissue of a subset of sporadic cases. CDK4/CCND2 amplifications and other copy number alterations have been identified by genomic profiling of CNS medulloepithelioma. There are no established environmental or dietary risk factors. Most cases arise sporadically. Family history of DICER1-associated tumors (pleuropulmonary blastoma in a sibling, multinodular goiter in a parent) should trigger genetic counselling and germline DICER1 testing.

Intraocular medulloepithelioma most commonly presents in the first decade of life with: decreased visual acuity or loss of vision in the affected eye; leukocoria (white pupillary reflex) — the most common presenting sign, shared with retinoblastoma; strabismus; and anterior chamber changes including iris heterochromia, rubeosis iridis (iris neovascularization), secondary glaucoma causing buphthalmos (enlargement of the eyeball in infants), or a visible ciliary body mass on slit-lamp examination. Pain from secondary glaucoma is a late symptom. CNS medulloepithelioma presents with features typical of its anatomical location: headache, vomiting, and ataxia from posterior fossa involvement; hydrocephalus and raised intracranial pressure from periventricular tumors; or lower limb weakness and sphincter dysfunction from cauda equina lesions. Spinal seeding (leptomeningeal dissemination) occurs in approximately 20–30% of CNS cases at diagnosis, causing polyradiculopathy.

Intraocular medulloepithelioma is diagnosed primarily by clinical and ultrasound examination — an experienced ocular oncologist can diagnose the majority of cases without biopsy. Ocular ultrasound (B-scan) demonstrates an irregular mass within the ciliary body with internal reflectivity and calcification in teratoid forms. MRI orbit with gadolinium delineates the tumor extent, extraocular extension, and optic nerve involvement. Anterior segment OCT and UBM (ultrasound biomicroscopy) provide high-resolution imaging of the ciliary body mass. Fluorescein angiography may show feeder vessels. In children under 3 with leukocoria, retinoblastoma must be excluded urgently; unlike retinoblastoma, medulloepithelioma is typically unilateral with a characteristic location at the pars plana/ciliary body. Histopathological examination of the enucleated eye confirms diagnosis: ribbons, cords, and tubular structures of primitive neuroepithelium with/without rosettes, teratoid elements, or malignant areas. CNS medulloepithelioma is diagnosed by MRI brain/spine (with gadolinium) and CSF cytology; stereotactic biopsy or surgical resection provides tissue. DICER1 molecular testing of tumor DNA is standard.

Intraocular medulloepithelioma: Enucleation (surgical removal of the entire eye) is the primary treatment for tumors occupying more than one-quarter of the eye, those with extraocular extension, secondary glaucoma, or poor visual prognosis in the affected eye. Enucleation is curative for localized benign and well-differentiated malignant forms with 5-year survival exceeding 90% for localized disease. For small tumors with preserved visual potential, conservative management — laser photocoagulation, cryotherapy, or intralesional anti-VEGF injection — has been reported in case series, but evidence is limited. Adjuvant systemic chemotherapy is considered for malignant forms or when extraocular extension is found at enucleation. CNS medulloepithelioma: Maximal safe surgical resection is the primary treatment. Adjuvant treatment follows COG (Children's Oncology Group) and SIOP (International Society of Paediatric Oncology) protocols for embryonal tumors: high-dose alkylating chemotherapy (cyclophosphamide, etoposide, vincristine, carboplatin) with craniospinal irradiation (CSI) for patients ≥3 years; chemotherapy-only approaches for infants to defer radiation. Prognosis for malignant CNS medulloepithelioma is poor: 5-year survival approximately 30–50%.

Prognosis for medulloepithelioma depends on anatomical location, histological grade (malignant vs. benign teratoid), and extent of disease at diagnosis. Intraocular medulloepithelioma — benign or well-differentiated malignant forms localized to the eye — has an excellent prognosis after enucleation, with 5-year disease-free survival exceeding 90% for localized disease. Malignant intraocular forms with extraocular extension or poorly differentiated histology have recurrence rates of 20–30% and require adjuvant systemic chemotherapy; 5-year survival decreases to 70–80% in this subgroup. CNS medulloepithelioma has a significantly worse prognosis: 5-year overall survival is approximately 30–50% for malignant forms, with the poorest outcomes in infants (who cannot receive craniospinal radiation) and in patients with leptomeningeal dissemination at diagnosis. Complete surgical resection is the most important prognostic factor for CNS disease; gross total resection is strongly associated with better long-term outcomes. Leptomeningeal spread at diagnosis reduces 5-year survival to below 20%. Long-term survivors of CNS medulloepithelioma require annual MRI surveillance for at least 10 years due to the risk of late recurrence. Germline DICER1 carriers require surveillance for associated tumors (pleuropulmonary blastoma, ovarian sex cord-stromal tumors, thyroid carcinoma) throughout life. Intraocular medulloepithelioma survivors require periodic monitoring of the contralateral eye for bilateral disease in known DICER1 syndrome patients.

No preventive strategies for sporadic medulloepithelioma are established. All patients with intraocular or CNS medulloepithelioma should undergo germline DICER1 testing; identification of a germline mutation enables surveillance of first-degree relatives. DICER1 carriers require annual chest CT (pleuropulmonary blastoma surveillance in children under 8), thyroid ultrasound, abdominal ultrasound (cystic nephroma, ovarian tumors), and ophthalmological evaluation. After enucleation for intraocular medulloepithelioma, the contralateral eye is examined regularly as bilateral cases — though rare — are reported in DICER1 carriers. Malignant intraocular medulloepithelioma requires systemic staging (MRI brain/spine, bone marrow biopsy) and adjuvant chemotherapy considerations at a specialized center. Lifelong surveillance with annual MRI is recommended for CNS medulloepithelioma survivors.

Any child with a white pupillary reflex (leukocoria) must be evaluated urgently by a pediatric ophthalmologist within 48 hours to exclude retinoblastoma and other intraocular malignancies including medulloepithelioma — the priority is to preserve life, then vision. Leukocoria detected in a photo (absence of the normal red reflex) by a parent or through newborn screening is sufficient justification for immediate ophthalmological referral. A child with new-onset strabismus, iris color change (heterochromia), or a painful red eye should also be urgently evaluated. For CNS medulloepithelioma: any child with progressive headache, vomiting, and ataxia requires emergency MRI brain. Families with known DICER1 syndrome should ensure their children are enrolled in a dedicated surveillance program supervised by a clinical geneticist and specialist oncologist.